Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Rana Nagarkatti"'
Autor:
Fernanda Fortes de Araujo, Rana Nagarkatti, Ana Lia Mazzeti, Karolina Ribeiro Gonçalves, Lívia de Figueiredo Diniz, Isabela Campos do Vale, Olindo Assis Martins-Filho, Alain Debrabant, Maria Terezinha Bahia, Andréa Teixeira-Carvalho
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
IntroductionChagas disease (CD) is caused by the protozoan parasite Trypanosoma cruzi. Although endemic mainly in Latin America, CD has become a global public health problem due to migration of infected individuals to non-endemic regions. Despite pro
Externí odkaz:
https://doaj.org/article/60fe01f1e4f84f4b87ea28d4a4c2b88a
Autor:
Katarzyna I. Jankowska, Rana Nagarkatti, Nirmallya Acharyya, Neetu Dahiya, Caitlin F. Stewart, Ruairidh W. Macpherson, Mark P. Wilson, John G. Anderson, Scott J. MacGregor, Michelle Maclean, Neil Dey, Alain Debrabant, Chintamani D. Atreya
Publikováno v:
Frontiers in Medicine, Vol 7 (2020)
The introduction of pathogen reduction technologies (PRTs) to inactivate bacteria, viruses and parasites in donated blood components stored for transfusion adds to the existing arsenal toward reducing the risk of transfusion-transmitted infectious di
Externí odkaz:
https://doaj.org/article/5492a36c36e94939873e20cc0f69fe6d
Autor:
Erica Silberstein, Carylinda Serna, Stenio Perdigão Fragoso, Rana Nagarkatti, Alain Debrabant
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0195879 (2018)
Chagas disease, caused by the intracellular protozoan Trypanosoma cruzi, affects 8-10 million people worldwide and represents a major public health challenge. There is no effective treatment or vaccine to control the disease that is characterized by
Externí odkaz:
https://doaj.org/article/796b3f787f5f4343a6976d61fd7be617
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 9, Iss 1, p e3451 (2015)
Drug discovery initiatives, aimed at Chagas treatment, have been hampered by the lack of standardized drug screening protocols and the absence of simple pre-clinical assays to evaluate treatment efficacy in animal models. In this study, we used a sim
Externí odkaz:
https://doaj.org/article/f531793561e24b30b3ae998a996b8232
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 8, Iss 1, p e2650 (2014)
Chagas disease affects about 5 million people across the world. The etiological agent, the intracellular parasite Trypanosoma cruzi (T. cruzi), can be diagnosed using microscopy, serology or PCR based assays. However, each of these methods has their
Externí odkaz:
https://doaj.org/article/2bbd85133e5e46dd86c588f08a3270ca
Autor:
Rana Nagarkatti, Vaibhav Bist, Sirena Sun, Fernanda Fortes de Araujo, Hira L Nakhasi, Alain Debrabant
Publikováno v:
PLoS ONE, Vol 7, Iss 8, p e43533 (2012)
Trypanosoma cruzi, a blood-borne parasite, is the etiological agent of Chagas disease. T. cruzi trypomastigotes, the infectious life cycle stage, can be detected in blood of infected individuals using PCR-based methods. However, soon after a natural
Externí odkaz:
https://doaj.org/article/f38b66785e0f4727b6990cf169390fa7
Autor:
Dewal Jani, Rana Nagarkatti, Wandy Beatty, Ross Angel, Carla Slebodnick, John Andersen, Sanjai Kumar, Dharmendar Rathore
Publikováno v:
PLoS Pathogens, Vol 4, Iss 4, p e1000053 (2008)
When malaria parasites infect host red blood cells (RBC) and proteolyze hemoglobin, a unique, albeit poorly understood parasite-specific mechanism, detoxifies released heme into hemozoin (Hz). Here, we report the identification and characterization o
Externí odkaz:
https://doaj.org/article/a688632aec0f42dcb572510f2dc426b2
Autor:
Cristina Alonso-Vega, Julio A Urbina, Sergi Sanz, María-Jesús Pinazo, Jimy José Pinto, Virginia R Gonzalez, Gimena Rojas, Lourdes Ortiz, Wilson Garcia, Daniel Lozano, Dolors Soy, Rosa A Maldonado, Rana Nagarkatti, Alain Debrabant, Alejandro Schijman, M Carmen Thomas, Manuel Carlos López, Katja Michael, Isabela Ribeiro, Joaquim Gascon, Faustino Torrico, Igor C Almeida
Publikováno v:
BMJ Open
IntroductionChagas disease (CD) affects ~7 million people worldwide. Benznidazole (BZN) and nifurtimox (NFX) are the only approved drugs for CD chemotherapy. Although both drugs are highly effective in acute and paediatric infections, their efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3c0a8f014780e0a66555d5baf788858
https://doi.org/10.1136/bmjopen-2021-052897
https://doi.org/10.1136/bmjopen-2021-052897
Autor:
Stenio Perdigão Fragoso, Erica Silberstein, Rana Nagarkatti, Carylinda Serna, Alain Debrabant
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0195879 (2018)
PLoS ONE
PLoS ONE
Chagas disease, caused by the intracellular protozoan Trypanosoma cruzi, affects 8-10 million people worldwide and represents a major public health challenge. There is no effective treatment or vaccine to control the disease that is characterized by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b129c784f4cac03bb059b8b811099789
http://europepmc.org/articles/PMC5908157?pdf=render
http://europepmc.org/articles/PMC5908157?pdf=render
Publikováno v:
Drug Discovery Today: Therapeutic Strategies. 3:153-158
Malaria parasite degrades hemoglobin and releases toxic heme, which is quickly detoxified by the parasite. Whereas several important antimalarials like artemisinin and chloroquine disrupt this process, the mechanism of heme detoxification is not full
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90d26ab1498dc0dd9486238bc874bcf9
https://doi.org/10.1016/j.ddstr.2006.06.003
https://doi.org/10.1016/j.ddstr.2006.06.003